The effect of finasteride and dutasteride on the growth of wpe1-na22 prostate cancer xenografts in nude mice by Opoku-Acheampong, Alexander Boadu
  
 
 
 
THE EFFECT OF FINASTERIDE AND DUTASTERIDE ON THE GROWTH OF WPE1-
NA22 PROSTATE CANCER XENOGRAFTS IN NUDE MICE 
 
 
by 
 
 
ALEXANDER BOADU OPOKU-ACHEAMPONG 
 
 
 
B.Sc., UNIVERSITY OF GHANA, 2005  
 
 
 
A THESIS 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
 
MASTER OF SCIENCE 
 
 
 
Department of Human Nutrition 
College of Human Ecology 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2011 
 
Approved by: 
 
Major Professor 
Dr. Brian L. Lindshield 
  
 
 
Abstract 
5α-reductase 1 (5αR1) and 5α-reductase 2 (5αR2) convert testosterone into the more 
potent androgen, dihydrotestosterone (DHT), that is responsible for regulating prostate growth 
and proliferation. 5αR2 is the main isoenzyme in normal prostate tissue, however prostate tumors 
have increased 5αR1 and decreased or unchanged 5αR2 expression. Previously, finasteride 
(5αR2 inhibitor) treatment begun 3 weeks after tumor implantation had no effect on Dunning 
R3327-H rat prostate tumor growth. We believe the tumor compensated for finasteride treatment 
by increasing tumor 5αR1 activity to produce dihydrotestosterone to stimulate its growth. We 
hypothesize that finasteride treatment would not significantly alter tumor growth even if begun 
before tumor implantation, while dutasteride (dual 5αR1 & 5αR2 inhibitor) treatment would 
decrease tumor growth regardless if treatment is begun before or after tumor implantation. Sixty, 
8-week old male nude mice were randomized to Control, Pre-Finasteride, Post-Finasteride, Pre-
Dutasteride and Post-Dutasteride diet groups (all diets contained 83.3 mg drug/kg diet). Pre 
groups began their treatment diets 1-2 weeks prior to tumor implantation, while post groups 
began their treatment diets 3 weeks after tumor implantation. Tumors were implanted by 
subcutaneous injection of 1 x 10
5
 WPE1-NA22 human prostate cancer cells in Matrigel™ and 
allowed to grow for 22 weeks. Tumor areas, body weights, and feed intakes were measured 
weekly. At study conclusion, prostate and seminal vesicle weights were significantly decreased 
in all treatment groups versus the control. Dutasteride intake also significantly reduced seminal 
vesicle weights compared to finasteride intake. There were no significant differences in final 
tumor areas or tumor weights between groups, likely due to poor tumor growth. In follow-up 
studies, proliferation of WPE1-NA22 prostate cancer cells, and its parent line RWPE-1 prostate 
  
epithelial cells, were unaltered by treatment with testosterone, DHT, or the synthetic androgen 
mibolerone, suggesting that these cell lines are not androgen-sensitive. Thus, the lack of response 
to androgen treatment by WPE1-NA22 prostate cancer cells may explain the inadequate tumor 
growth observed. 
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Chapter 1 - Introduction 
Prostate cancer is the second leading cause of cancer related deaths and was estimated to 
account for one out of every four newly diagnosed cancers in American men in 2010 [1]. Within 
the prostate, the main circulating androgen testosterone is converted by the enzymes 5α-
reductase 1 and 2 into the more potent dihydrotestosterone (DHT), which binds with up to 10-
fold higher affinity to the androgen receptor (AR) than testosterone [2,3]. The binding of DHT to 
androgen receptor causes gene transcription of androgen-regulated genes and promotes cellular 
proliferation in androgen-dependent cancerous tissues [4]. At initial stages of prostate cancer, 
most cancers rely on androgens for growth, and thus are referred to as androgen-dependent [5]. 
Inhibiting androgen production and/or blocking its action have served as means to combat 
prostate cancer [6].  
5α-reductase 1 is the major isoenzyme in human liver and non genital skin, while 5α-
reductase 2 is the major isoenzyme in prostate, epididymis, seminal vesicles and genital skin. [7]. 
Most studies report increased levels of 5α-reductase 1 and decreased levels of 5α-reductase 2 in 
prostate cancer [8-12], others observed increased 5α-reductase 1 mRNA expression and no 
significant changes in 5α-reductase 2 mRNA expression in prostate cancer versus normal cancer 
[13], increased expression of both isoenzymes in prostate cancer [6], or loss of expression of 
both isoenzymes in metastatic prostate cancer [14]. There are two 5α-reductase inhibitors, 
finasteride (5α-reducatse 2 inhibitor) and dutasteride (5α-reductase 1 and 2 inhibitor), commonly 
used to treat benign prostatic hyperplasia (BPH) [15]. There is also the potential that these 5α-
reductase inhibitors could be used to prevent or treat prostate cancer by reducing DHT levels 
[16].  
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To this end, the Prostate Cancer Prevention Trial (PCPT) found that finasteride decreased 
prostate cancer prevalence by 24.8% [17]. Similarly the Reduction by Dutasteride of Prostate 
Events (REDUCE) trial found a 23% reduction in prostate cancer incidence with dutasteride 
administration [18]. In animal models, finasteride did not inhibit growth of the Dunning R-
3327H rat prostate tumors while dutasteride did [19]. In nude mice bearing LNCaP human 
prostate cancer xenografts, both finasteride and dutasteride reduced tumor growth, although 
dutasteride was more effective at an equimolar dose [19]. Similarly in another rat study, 
finasteride significantly decreased weights of the androgen-sensitive tissues, seminal vesicles 
and prostate, but did not decrease Dunning R-3327H tumor growth [20].  
In these animal studies, finasteride and dutasteride administration began after tumors 
were already established so it is possible that if finasteride was administered before tumor 
implantation, it might significantly reduce tumor growth. On the other hand, regardless of when 
finasteride treatment is begun, prostate cancer cells may compensate for 5α-reductase 2 
inhibition by increasing 5α-redutase 1 expression and/or activity. Thus, the dual inhibitory effect 
of dutasteride may offer an advantage over finasteride. We examined the effect of finasteride and 
dutasteride diets begun (1 week) before or (3 weeks) after subcutaneous injection of WPE1-
NA22 human prostate cancer cells into the rear flanks of male nude mice. We chose to use 
WPE1-NA22 prostate cancer xenografts because these are human cancer cells that can be 
cultured in vitro, form tumors that are not invasive and have growth rates and pathology similar 
to the Dunning R-3327H tumor [21,22].  
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Chapter 2 - Literature Review 
 Prostate Cancer 
Prostate cancer accounts for one out of every four newly diagnosed cancers in American 
men with an estimated 217,730 new cases in 2010. Early detection is possible through prostate 
specific antigen (PSA) testing although the latent nature and limited clinical symptoms 
associated with the disease can hinder its detection. Factors such as age, race, socioeconomic 
status and genetic predisposition play a significant role in prostate cancer occurrence. Mortality 
is variable with some men living for many years without showing any clinical symptoms while 
others die a short time after diagnosis [1]. 
 Prostate Intraepithelial Neoplasia (PIN) and Benign Prostatic Hyperplasia 
(BPH) 
Two other common prostate conditions are prostate intraepithelial neoplasia (PIN) and 
benign prostatic hyperplasia (BPH). PIN is a microscopic lesion in the prostate believed to be a 
pre-cancerous condition [23]. Over 50% of men aged 60 or over are believed to suffer from BPH 
[24], which is caused by increased proliferation of prostate stromal and epithelial cells [25]. BPH 
is clinically distinguished by the progressive development of lower urinary tract symptoms [26] 
as a result of the compression of the urethra caused by enlargement of the prostate [24]. 
Symptoms include nocturia, incomplete emptying, urinary hesitancy and weak stream [26]. 
 Prostate Specific Antigen, Gleason Grading and Tumor, Lymph Node and 
Metastasis (TNM) Staging 
The prostate epithelium produces prostate specific antigen (PSA), a glycoprotein that 
since 1987 has been used as a biomarker for prostate cancer screening [27]. Although men with 
serum PSA levels greater than 4 ng/ml are regarded as being at increased risk, this threshold is 
4 
 
controversial because men with PSA levels below this threshold also develop prostate cancer 
[28,29]. Typically, men with prostatic diseases including prostate cancer have higher serum PSA 
levels because of increased production coupled with the architectural distortions within the 
prostate [27]. PSA is found free in circulation as well as bound to the serum proteins α1-
antichymotrypsin and α2-macroglobulin [30]. Total serum PSA can be increased in other 
prostatic conditions making it a less sensitive and specific tumor biomarker [31]. Subsequently, 
the ratio of free PSA to total PSA has been reported to be better in distinguishing prostate cancer 
from BPH [32]. Other parameters have also been introduced to improve PSA as a biomarker of 
prostate cancer such as PSA density [33], serial PSA measurements [28], age and race specific 
reference ranges [34] and prostate specific velocity (rate of change of PSA over time) [35].  
 Gleason grading is a prostate cancer measure that uses five histologic grade patterns 
ranging from 1 to 5. A histologic score is obtained by the summation of the primary grade 
pattern and the secondary grade pattern to give a range from 2 to 10. In situations with only one 
grade pattern present, it is multiplied by 2 to give the histologic score [36]. The tumor, lymph 
node and metastasis (TNM) is another staging method of prostate cancer. The T describes the 
size of the tumor, N describes the regional lymph nodes, and M describes distant metastasis. A 
range of numbers is used to classify the parameters T, N and M (eg. T1: is not palpable or 
visible, T2: confined within the prostate and T3: through prostate capsule; NX: cannot evaluate 
regional lymph nodes, N0: no spread to regional lymph nodes N1: spread to regional lymph 
nodes; MX: cannot evaluate distant metastasis, M0: no distant metastasis; M1: distant 
metastasis) [37,38,39]. 
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 Androgens 
Androgens are male steroid hormones that control the development and differentiation of 
the male reproductive system [40]. Within the prostate, the main circulating androgen 
testosterone is converted by the enzymes 5α-reductase 1 and 2 into dihydrotestosterone (DHT), 
the more potent androgen required for normal growth and development of the prostate [41-43]. 
Although both testosterone and DHT bind to the androgen receptor, DHT binds with a 10-fold 
higher affinity [2,3]. The binding of DHT to the androgen receptor causes the transcription of 
androgen-regulated genes and cellular proliferation in androgen-sensitive tissues [4]. At initial 
stages of prostate cancer, most are referred to as androgen-dependent. However, prostate cancer 
often becomes androgen-independent when patients undergo androgen ablation treatment for an 
extended period. At this stage, prostate cancer does not depend on androgens for growth, 
meaning it can grow even under androgen-depleted conditions. The mechanism through which 
prostate cancer becomes androgen-independent is not known but could be a result of genetic 
change in prostate cancer cells, androgen receptor (AR) hypersensitivity, ligand-independent AR 
activation, AR bypass, and change of AR specificity by mutation [5]. 
5α-Reductase Enzymes and 5α-Reductase Inhibitors 
5α-reductase 1 is the major isoenzyme in human liver and non genital skin while 5α-
reductase 2 is the major isoenzyme in prostate, epididymis, seminal vesicles and genital skin [7]. 
5α-reductase 1 and 2 enzymes are pH dependent and are maximally active at alkaline and acidic 
pH, respectively [44]. Most literature report increased levels of 5α-reductase 1 and decreased 
levels of 5α-reductase 2 in prostate cancer [8-12], others observed increased 5α-reductase 1 
mRNA expression and no significant changes in 5α-reductase 2 mRNA expression in prostate 
cancer versus normal cancer [13], increased expression of both isoenzymes in prostate cancer 
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[6], or loss of expression of both isoenzymes in metastatic prostate cancer [14]. Recently, 5α-
reductase 3 has been identified and found to be overexpressed in hormone-refractory prostate 
cancer cells and tissues [45]. 
There are two inhibitors of 5α-reductase 1 and 2 commonly used to treat BPH, finasteride 
(trade name Proscar
®
) and dutasteride (trade name Avodart
®
). In addition finasteride (trade name 
Propecia
®
) is also used for treating male pattern baldness [17,46]. They are both azasteroids 
meaning they contain heterocyclic nitrogen rings [7]. A structural modification in dutasteride 
increases its serum half-life and inhibition potency [19]. Finasteride competitively inhibits 5α-
reductase 2 activity and reduces serum DHT levels by approximately 70%, while dutasteride 
competitively inhibits both 5α-reductase 1 and 2 isoenzymes and decreases serum DHT by 
greater than 90% [47,48]. This dual inhibition may offer an advantage over finasteride and is 
approximately 60 times more potent than finasteride in reducing 5α-reductase activity [49,50]. 
 Cell Lines for Prostate Cancer Research 
The two types of prostate cell culture options are primary or immortalized cells. Primary 
cell cultures are derived directly from tumors and have the advantage of being more 
representative of their original tissue. The disadvantages however are the limited access, finite 
lifespan and specific culturing techniques for maintaining these cells. Immortalized cell lines are 
derived from normal or cancer tissues and they offer the advantage of having an unlimited 
lifespan. However, the disadvantage of these lines is that they are not as representative of the 
original tissues [51,52].  
Extremely poor growth of human prostate tumor tissue in culture and/or in nude mice has 
been, and continues to be, a major challenge for selecting a prostate cancer cell line. The poor 
growth of human prostate tissue in culture may be explained by the fact that total and free 
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testosterone levels in 10% fetal calf serum (commonly used in media for in vitro culture of cells) 
are more than 100-fold lower than is found in serum from intact adult human males. Even more 
surprising is that total serum testosterone levels in fetal bovine serum are slightly lower than 
serum testosterone levels from castrated adult human males [53].  
The choice of a cell line for prostate cancer research depends on a number of factors such 
as androgen-sensitivity, doubling time, and tumor forming potential in immunocompromised 
mice. The three most widely used immortalized prostate cancer cell lines are LNCaP, DU-145, 
and PC-3 cells, which are all derived from metastasized human prostate cancer [54]. LNCaP 
cells were derived from lymph node metastasis and are androgen-sensitive meaning androgens 
stimulate their growth [55-57]. DU-145 cells were isolated from brain metastasis while PC-3 
cells were derived from bone metastasis; both lines are androgen-insensitive [58,59]. Over the 
years, other cell lines have also been developed such as the RWPE-1 prostate epithelial cells 
derived from the peripheral zone of a histologically normal adult human prostate and 
immortalized using human papilloma virus-18 (HPV-18) [60]. To create cancerous cells, RWPE-
1 cells were transformed using the carcinogen N-methyl-N-nitrosourea and subcutaneously 
injected into nude mice to form tumors. Second generation tumors were then cultured, 
progressively, to create the WPE1-NA22, WPE1-NB14, WPE1-NB11 and WPE1-NB26 cell 
lines [22]. Another cell line, the PC-346C cells are human, androgen-sensitive cells derived from 
the transurethral resection of a primary prostate tumor [61].  Some common cell lines and their 
individual characteristics are listed below. 
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Table 2.1 Characteristics of Common prostate cell lines [22,55-60]  
   
Cell line Origin Androgen sensitive 
/dependent /independent 
Tumor forming 
potential 
DU-145 Brain AS Yes 
LNCaP Lymph node AS Yes 
PC-3 Bone AI  
PC-346C Prostate AS/AI Yes 
WPE1-NA22 Prostate AS Yes 
RWPE-1 Prostate AS/AI No 
 
 Spontaneous, Carcinogen-Induced, and Hormone-Induced Models of 
Prostate Cancer 
There are a limited number of laboratory animal models that develop spontaneous 
prostate cancer.  Dogs and ACI Seg rats are the only animals that develop prostate cancer 
spontaneously [62,63]. Similarities between human and canine prostate cancer include late age of 
onset, metastatic propensity and androgen-independence associated with advanced stages of the 
disease [62]. Regardless of these similarities, the dog is not commonly used for prostate cancer 
research.  
ACI Seg rats spontaneously develop prostate cancer in 35-40% of cases by 30 months 
with no significant stromal inflammation. Carcinogen-induced models include the Fischer F344 
rat, which develop tumors in the seminal vesicles, anterior, ventral, and dorsolateral lobes of the 
prostate after administration of the carcinogen 3,2’-dimethyl-4-aminobiphenyl (DMAB) and 
testosterone propionate (TP) [64]. N-nitroso-N-methylurea (NMU) is another carcinogen that is 
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capable of chemically inducing cancer in this model [65]. The advantage of the Fischer F344 
model is their long life span and androgen-dependent tumors; however their inability to develop 
tumor in bones limit their usability for some metastatic studies. The Noble rat when treated with 
testosterone and estradiol has 100% incidence of prostate cancer in the dorsolateral region 
although there is limited metastasis [64].  
 Xenografts and Transplantable Tumor Models 
Nude mouse lack a functional thymus, as a result they can accept subcutaneous grafts of 
human tumor or cancer cells. To increase the tumor take rate, cancer cells are often mixed with 
Matrigel™ before injection. In prostate cancer xenograft models, prostate cancer cells are 
subcutaneously injected into flanks or shoulders, orthotopically injected into the prostate, or 
implanted into the sub-renal capsule of immunocompromised animal models [66]. LNCaP and 
PC-346 are human androgen-sensitive xenografts that have been used for studying the 
progression of prostate cancer from androgen-dependent to androgen-independent [67,68]. 
CWR22 cells were developed from a primary prostate cancer and are also ideal for studying the 
progression of prostate cancer from androgen-dependence to androgen-independence [69]. The 
WPE1-NA22, WPE1-NB14, WPE1-NB11 and WPE1-NB26 prostate cancer cell lines, derived 
from RWPE-1 prostate epithelial cells, can be used to study carcinogenesis, progression, 
intervention and chemoprevention. The WPE1-NA22 and WPE1-NB14 are both non-invasive 
while WPE1-NB11 and WPE1-NB26 are slightly and highly invasive, respectively. The WPE1-
NA22 xenografts have the slowest doubling times and form well-differentiated tumors [22]. The 
Dunning R3327-H transplantable tumor was derived from a spontaneous tumor in a Copenhagen 
rat. It is slow-growing, non-metastatic, androgen-sensitive tumor that responds to dietary 
interventions [21,70]. 
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 Transgenic Prostate Cancer Models 
Transgenic mouse models have been developed that mimic the complexity of prostate 
carcinogenesis. Genes such as the rat probasin and human prostate specific antigen (PSA) are 
introduced into the germline of animal models to create stable transgenic models that can be 
propagated [71]. Two variants of the rat probasin promoter have been used to develop two 
transgenic models; the transgenic adenocarcinoma of the mouse prostate (TRAMP) and LPB-
Tag transgenic mice (LADY). The most well characterized and used transgenic prostate cancer 
model is TRAMP mice [72,73]. In these mice the expression of the SV40 large and small T 
antigen is driven by a region of the prostate-specific rat probasin promoter [74,75]. TRAMP 
mice develop high-grade PIN at 12 weeks old with poorly differentiated and invasive carcinoma 
appearing between 18-30 weeks and metastasizing to lymph nodes and lungs and occasionally 
kidney, bone and adrenal glands [76]. 
The LADY model uses a large fragment of the rat probasin promoter to direct prostate 
SV40 large T antigen expression. Although tumor formation varies, typically, at 10 weeks, 
LADY mice develop PIN followed by high grade PIN at 20 weeks followed by poorly or 
undifferentiated cancer [77,78].  Male transgenic mice that carry the C3(1) SV 40 early region 
transgene develop PIN and invasive carcinoma after 8 and 28 weeks, respectively. Another 
mouse model that carries the fetal globin/SV40 early region transgene develops tumors in the 
ventral and dorsolateral prostate. Seventy-five percent of heterozygous and 100% for mice 
homozygous for the transgene develop tumors. The development of tumor in this model is 75% 
for mice. Mice with the Probasin/rasT24 transgene develop hyperplasia in both the ventral and 
dorsolateral prostate; however, PIN is not seen in this model [71]. 
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 Cell Culture Studies with Finasteride and Dutasteride 
Finasteride (1-5 µM) significantly reduced the growth of LNCaP cells treated with 
testosterone or dihydrotestosterone by as much as 50-60% [79,80]. Dutasteride (0.5-10 µM) 
significantly inhibited >99% of the conversion of 
3
H testosterone to 
3
H-DHT in LNCaP cells 
[81]. Dutasteride (1 µM) reduced both viability and cell numbers while 10 µM reduced cell 
proliferation by approximately 50% in LNCaP cells. [3]. Finasteride (0.4-1.6 µM) significantly 
increased the proliferation of the normal prostate cell line CRL-2221, DU-145, PC-3 and LNCaP 
cells. Increasing finasteride doses beyond 1.6 µM had no effect on the growth of CRL-2221s, 
LNCaPs and PC-3s, but significantly decreased growth of DU-145 cells. Dutasteride (0.4-50 
µg/well) significantly inhibited the growth of PC-3, DU-145, CRL-2221 and LNCaP cells [82]. 
Finasteride (0-50 µM) significantly reduced cell viability in LNCaP, PC3 and RWPE-1 cells. 
Dutasteride (0-50 µM) significantly inhibited the growth of RWPE-1, LNCaP and PC3 cells 
[83]. 
 Animal Studies with Finasteride and Dutasteride 
Finasteride (5 and 20 mg/kg/day) administered to young adult male Sprague-Dawley rats 
for 28 days significantly reduced ventral prostate, seminal vesicle, and epididymis weights [53]. 
In a similar study, finasteride (25 mg/kg/day) administered to rats for 7 days significantly 
reduced ventral prostate weight and decreased 5α-reductase activity [55]. Administration of a 
higher dose of finasteride (160 mg/kg/day) for 15 days to rats significantly reduced dorsolateral 
prostate DHT, ventral prostate DHT and circulating DHT levels by 86%, 94% and approximately 
98%, respectively. These reductions in prostatic DHT levels were also associated with significant 
decreases in dorsolateral and ventral weights by 39% and 46%, respectively. In a different rat 
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study, finasteride treatment (80 mg/kg/day) for 6 months significantly decreased dorsolateral and 
ventral lobe weights by 46% and 67%, respectively [56]. 
Dutasteride (2 mg/kg every 2 days) treatment for 4 weeks of weeks significantly 
decreased LADY mouse ventral prostate, dorsolateral prostate and seminal vesicle weights. A 
lower dose of dutasteride (0.2 mg/kg every 2 days) also significantly decreased seminal vesicle 
and dorsolateral prostate weights, but not ventral prostate weights. When treatment initiation was 
either delayed for 4 weeks or treatment extended to 8 weeks, dutasteride (1 mg/kg per day) 
significantly reduced dorsolateral prostate and seminal vesicle weights, but not ventral prostate 
weights [54]. 
Finasteride (70 mg/kg/day) and dutasteride (100 mg/kg/day) treatments significantly 
decreased LNCaP prostate cancer growth although the latter treatment was better at equimolar 
concentrations. Finasteride treatment (0.7, 7, 70  mg/kg/day) in rats bearing the Dunning R-
3327H rat prostate tumors reduced the weight and DHT concentration of ventral prostate, but 
had no effect on tumor weights. However dutasteride (1, 10, 100 mg/kg/day) significantly 
reduced ventral prostate weight, DHT concentrations and Dunning R-3327H tumor growth [19]. 
These Dunning R-3327H finasteride results are similar to another study that found a significant 
reduction in prostate and seminal vesicles weights after finasteride (5 mg/kg body weight/6 
day/week) treatment, but no effect on Dunning R3327-H tumor area or weight [20]. 
 Clinical Trials with Finasteride and Dutasteride 
The Prostate Cancer Prevention Trial (PCPT), a randomized, double-blind, placebo-
controlled clinical trial of 18,882 men with normal digital rectal examination and PSA ≤ 3 ng/ml 
tested the potential of finasteride to prevent prostate cancer in men aged ≥55 years old. Men 
were randomly assigned to finasteride (5 mg/day) or placebo and after seven years finasteride 
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significantly reduced the prevalence of prostate cancer by 24.8%, although significantly higher 
Gleason scores were also observed in the finasteride group [17]. Similarly, the Reduction by 
Dutasteride of Prostate Cancer Events (REDUCE) was a placebo-controlled, randomized, 
double-blind clinical trial that recruited 8,000 men ≥50 years old with one negative prostate 
biopsy and a prostate specific antigen of between 2.5-10.3 ng/ml. Men were randomly assigned 
to receive a daily dose of 0.5 mg dutasteride or placebo and after 4 years there was a significant 
23% reduction in prostate cancer incidence in the dutasteride group [18]. In another trial, 46 men 
with clinical stage T1 and T2 prostate cancer were randomly assigned to receive 5mg of 
dutasteride or placebo daily for 6-10 weeks before radical prostatectomy. Dutasteride 
significantly decreased intraprostatic and serum DHT levels [84]. Another 4-month randomized 
study of 81 men who received dutasteride at doses of 0.5 or 3.5 mg/day prior to radical 
prostatectomy found PSA concentrations to be significantly lower in men receiving both doses of 
dutasteride compared to surgery alone [85].  
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Chapter 3 - Materials and Methods 
 Cell Lines 
RWPE-1 prostate epithelial cells and WPE1-NA22 cancer cells (ATCC, Manassas, VA) 
were cultured in serum-free keratinocyte media containing bovine pituitary extract and epidermal 
growth factor (GIBCO Invitrogen, Carlsband, CA). For the animal study, WPE1-NA22 cells 
were cultured in 75 cm
2
 flasks (Fisher Scientific, Pittsburg, PA), removed with trypsin (Sigma-
Aldrich, St. Louis, MO), and centrifuged for 7 minutes with 130 x G at 37°C. Supernatant was 
removed and cells reconstituted in Matrigel™ (BD Biosciences, Franklin Lakes, NJ) at a 
concentration of 5000 cells/µL. Twenty µL of Matrigel™ containing ~1 x 105 WPE1-NA22 
cancer cells was injected into each rear flank of nude mice using a Hamilton syringe holder 
(Hamilton, Reno, NV) fitted with a 1 mL syringe and a 25 gauge 5/8” needle (both from BD 
Biosciences). 
 Animals, Study Diets and Design 
Two cohorts of thirty (60 total) 8-week old male, nude mice (Charles Rivers, 
Wilmington, MA) were individually housed in sterile conditions. Mice were monitored daily, 
weighed weekly, and provided diets & water ad libitum. The Institutional Animal Care and Use 
Committee (IACUC) of Kansas State University approved this study.  
AIN93-G diets (Research Diets, New Brunswick, NJ) contained dutasteride (provided by 
GlaxoSmithKline Pharmaceuticals, Research Triangle Park, NC) and finasteride (Kemprotec, 
Middlesbrough, UK) at 83.3 mg/kg of diet to provide ~10mg drug/kg body weight. After receipt, 
mice were acclimated for 1 week, and then randomized into Control, Pre-Finasteride, Post-
Finasteride, Pre-Dutasteride and Post-Dutasteride groups (n =12, Figure 3.1). Pre-groups and 
post-groups began their treatment diets 1-2 weeks prior or 3 weeks after WPE1-NA22 cell 
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injection, respectively. The study was terminated at 22 weeks post tumor implantation. Mice 
were euthanized by CO2 inhalation and blood was immediately drawn via cardiac puncture, and 
centrifuged for 1 minute at 2000 x G to obtain serum. Tissues were dissected, flash frozen in 
liquid nitrogen, and stored in a freezer at -80°C. Tumor area was calculated using the formula: 
(length of tumor (L)/2 x width (W) of tumor/2) x pi. The average tumor area (Figure 4.2) in a 
group was calculated by dividing the sum of tumor area for the group by the total number of 
tumor sites in that group. For mice with no tumors, this was indicated with a zero. For tumor area 
in Figure A.1, tumor area was calculated by dividing the sum of tumor area for the group by the 
number of sites with tumors in that group.  
Control
(n = 12)
Pre-Finasteride
(n = 12)
Post-Finasteride
(n = 12)
Pre-Dutasteride
(n = 12)
Post-Dutasteride
(n = 12)
1-2 Weeks 3 Weeks 19 weeks1 Week 
Control
Control
Control
Finasteride
Control
Dutasteride
Control
Finasteride
Dutasteride
Begin 
control 
diets
Randomized 
into study 
groups, Pre 
diets begin 
(Week 0)
Tumor 
Implantation
Post Diets 
Begin Study 
Termination
 
Figure 3.1 Study design- After receipt, mice were acclimated for 1 week, and then randomized 
into Control, Pre-Finasteride, Post-Finasteride, Pre-Dutasteride and Post-Dutasteride groups (n 
=12). Pre-groups and post-groups began their treatment diets 1-2 weeks prior or 3 weeks after 
WPE1-NA22 cell injection, respectively. The study was terminated at 22 weeks post tumor 
implantation. 
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 In Vitro Androgen Treatment and Cell Viability 
RWPE-1 and WPE1-NA22 cells were plated at 10,000 cells per well in 96-well plates 
(Fisher Scientific, Pittsburg, PA). Twenty-four hours after plating, both cell lines were treated 
with various doses of testosterone (0.1 nM-30 nM), dihydrotestosterone (0.03 nM-100 nM), 
(both from Sigma Aldrich, St. Louis, MO) and the synthetic androgen mibolerone (0.01 nM-20 
nM) (PerkinElmer, Waltham, MA) in 0.1% ethanol. Media and treatments were changed every 
24 hours during the 5 day treatment period. Cell viability was determined using the CellTiter 96 
AQueous One Solution Assay (Promega Corporation, Madison, WI) with a Bio-Tek uQuant 
Plate reader (BioTek, Winooski, VT). 
 Statistical Analysis 
Data was analyzed using SAS 9.2 (SAS Institute Inc., North Carolina) with p<0.05 
considered statistically significant. ANCOVA with cohort as the covariate was used to initially 
analyze the animal study results. The covariate did not account for a significant amount of 
variance in all analyses, thus it was removed and ANOVA with Tukey’s test was used on pooled 
data from the two cohorts. Natural logs were used when data did not meet model assumptions. 
Kruskal Wallis non-parametric one-way ANOVA was used for tumor incidence. Androgen 
treatment cell viability data was analyzed using ANOVA with Dunnett’s test 
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Chapter 4 - Results 
Final body weights of the Pre-Finasteride group were significantly higher than the control 
(Table 4.1, p<0.05); despite there being no difference in daily feed intake among the groups, 
which ranged from 4.70 to 4.87 g/day. Tumor incidence was high, and not significantly different, 
between groups ranging from 86.4% to 95.5% (Figure 4.1). There was also no significant 
difference in tumor weights and tumor areas between groups (Table 4.1 & Figure 4.2). This was 
likely a result of poor tumor growth, as the largest average tumor diameter was 4.33 mm during 
the 22 week study. However, both finasteride and dutasteride significantly decreased prostate 
and seminal vesicle weights as a percent of body weight. In addition, there was a significant 
decrease in seminal vesicle weights in dutasteride groups versus finasteride groups (Table 4.1) 
The reduction in these androgen-sensitive tissues suggests that finasteride and dutasteride were 
exerting their anti-androgenic action. 
One explanation for this poor growth may be that WPE1-NA22 cells might not be 
androgen-sensitive like their parent RWPE-1 human prostate epithelial cells have been reported 
to be [60]. Thus, RWPE-1 human prostate epithelial and WPE1-NA22 cancer cell lines were 
treated with varying concentrations of the natural androgens testosterone and dihydrotestosterone 
and the synthetic androgen mibolerone. We found no significant difference in cell numbers in 
either cell type when treated with varying concentrations of androgens (Figures 4.3 & 4.4).  
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Table 4.1 Final body weights, tumor incidence, tumor weights, seminal vesicle weights as a 
percentage of body weight, and prostate weights as percentage of body weights
1
. 
 
Groups Final body 
weights
2
 (g) 
Final Tumor 
Incidence
3
 (%) 
Tumor 
weights
3    
(mg) 
Seminal 
vesicle 
weights
2
 (% 
body weight) 
Prostate 
weights
2
 
(% body 
weight) 
Control 30.6 ± 0.6
a
 87.5 35 ± 7 0.92 ± 0.05
a
 0.42 ± 0.05
a
 
Pre-Finasteride 33.2 ± 0.7
b
 86.4 25 ± 3 0.34 ± 0.02
b
 0.23 ± 0.02
b
 
Post-Finasteride 30.9 ± 0.8
a
 95.5 30 ± 4 0.38 ± 0.03
b
 0.27± 0.02
b
 
Pre-Dutasteride 29.4 ± 0.9
a
 95.0 36 ± 8 0.21 ± 0.01
c
 0.26 ± 0.02
b
 
Post-Dutasteride 30.2 ± 0.6
a
 86.4 22 ± 2 0.23 ± 0.02
c
 0.23 ± 0.03
b
 
 
1
 Data are means ± SEM, values with different letters are statistically different 
2
 n = 10-12  
3 
n = 20-24 
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Figure 4.1 Tumor incidence (n = 20-24), no significant differences 
Control 
Pre-Finasteride 
Post-Finasteride 
Pre-Dutasteride 
Post-Dutasteride 
20 
 
 
Figure 4.2 Tumor area (n= 20-24), no significant differences 
Control 
Pre-Finasteride 
Post-Finasteride 
Pre-Dutasteride 
Post-Dutasteride 
21 
 
 
Figure 4.3 RPWE-1 (plated at 10,000 cells/well) cell viability is not altered in response to daily 
treatment of testosterone (100 pmol - 30,000 pmol), dihydrotestosterone (30 pmol - 100,000 
pmol) and mibolerone (10 pmol - 20,000 pmol) after a 5-day treatment period. 
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Figure 4.4 WPE1-NA22 (plated at 10,000 cells/well) cell viability is not altered in response to 
daily treatment of testosterone (100 pmol - 30,000 pmol), DHT (30 pmol - 100,000 pmol) and 
mibolerone (10 pmol - 20,000pmol) after a 5-day treatment period. 
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Chapter 5 - Discussion 
In this study, we examined the effects of two 5α-reductase inhibitors, finasteride and 
dutasteride, pre and post tumor injection on the growth of WPE1-NA22 xenografts in nude mice. 
Tumor incidence was high for all groups ranging from 86.4% to 95.5%, which is similar to the 
tumor incidence reported in previous Dunning R-3327H rat prostate cancer studies [20,86]. 
However we were surprised by the poor growth of WPE1-NA22 xenografts in nude mice. The 
average tumor diameter from largest group was 4.33 mm, which is small compared to the ~7.26 
mm diameter that we back calculated from tumor volume previously reported for WPE1-NA22 
xenografts seven weeks after tumor implantation [22]. 
One factor that could have potentially influenced this variation in tumor size between 
both studies is the difference in number of WPE1-NA22 cancer cells injected into the flanks of 
mice. Webber and colleagues subcutaneously injected 5 x 10
5
 WPE1-NA22 cells which is five 
times more cells than what we injected in our study [22]. We injected fewer cancer cells because 
we were concerned that the tumor growth would be too rapid, given the reported size reported at 
7 weeks compared to Dunning R3327H tumors that are not even palpable until 9-10 weeks after 
tumor implantation. 
Another possible explanation for the poor growth of WPE1-NA22 xenografts in nude 
mice could be due to differences in the source of nude mice for our study and that used by 
Webber and colleagues. Additionally it is possible that WPE1-NA22 cells are not androgen-
sensitive, and thus do not respond to androgens for growth. We set out to investigate the latter 
possibility by determining whether WPE1-NA22 cells are androgen-sensitive like their parent 
cell line RWPE-1 human prostate epithelial cells [60].  
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Growth of RWPE-1 cells increased in a dose-dependent manner when treated with 
mibolerone (0.01-10 nM) [60]. We followed the methodology of Bello and colleagues who 
plated RWPE-1 cells at a density of 10,000 cells/well in 96-well plates and treated them with 
mibolerone (0.01-10 nM) for 5 days to see if we could repeat their results. The only changes 
were that our highest mibolerone treatment (20 nM) was double their highest mibolerone 
treatment (10 nM), and we also treated with testosterone and DHT. We chose concentrations of 
testosterone and DHT based on what several literature reported on cell growth of RWPE1 and 
WPE1-NA22 cells to the three different androgens [60,79,81]. It is important to note that 
physiological levels of both intraprostatic testosterone (~0.2-0.7 nM) [53] and 
dihydrotestosterone (5-18 nM) [19,87,88] in humans fell within the range of concentrations used. 
Interestingly, we found no difference in cell viability in either cell line in response to various 
concentrations androgen treatments. Thus, our results do not support that RWPE-1 cells are 
androgen-sensitive as they have been reported to be previously [60]. The only difference in 
methodology between the studies was the cell viability assays used. Bello et al. used methylene 
blue while we used MTS. Nevertheless, it is unlikely that these methodology differences explain 
the difference in outcomes. 
The lack of androgen-sensitivity exhibited by WPE1-NA22 cells may explain the poor 
tumor growth observed. Furthermore, a recent publication found androgen receptor and 5α-
reductase 1 protein levels to be undetectable in the nucleus and cytoplasm, respectively of 
RWPE-1 cells [83]. It is possible that the cell lines derived from this parent cell line may also 
have similar levels of these key proteins. Taken together, these results will have to be considered 
before using or interpreting results in RWPE-1 and its carcinogen-derived cell lines.  
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Another surprising result was significantly higher body weights in the Pre-Finasteride 
group despite no alteration in food intake. We believe based on the trend in growth seen in the 
Pre-Finasteride group that, that group may have been heavier from randomization because they 
were the heaviest group after only 1 week on the diet and continued to be heavier throughout the 
study. Data supporting finasteride increasing weight gain is sparse with a trial using finasteride 
reporting annual weight gain in men with high grade and low grade prostate cancer to be 0.01% 
and 0.25% higher than placebo respectively [89]. Similarly a study to determine the long term 
effect of finasteride on rats, found no significant change in body weight with finasteride 
treatment [90]. Diets in all treatment groups seemed however to have been well tolerated and 
there were no noted adverse effects.  
Despite no effect on tumor growth, all the treatments significantly decreased prostate and 
seminal vesicles weights. Finasteride reduced prostate weight in Pre and Post finasteride groups 
by 59% and 64.6%, respectively, while dutasteride decreased prostate weight in Pre and Post 
dutasteride groups to 62% and 56%, respectively. In rats finasteride (5, 20 and 25 mg/kg body 
weight) caused a reduction in the prostate to 49%, 54%, and 55% of control, respectively 
[91,92]. Canene-Adams et al. also reported that finasteride (5 mg/kg/body weight) significantly 
reduced rat prostate and seminal vesicle weight [20]. In our study, there was a significant 
decrease in seminal vesicle weights in dutasteride groups versus finasteride groups. Finasteride 
reduced seminal vesicles in Pre and Post-finasteride groups to 36% and 42% of control, 
respectively, while dutasteride decreased seminal vesicle weights to 23% and 25% of control, 
respectively. Mice in our study received approximately 13 mg/kg body weight/day of finasteride 
and dutasteride which is greater than previous studies that have provided 5 mg/kg body weight 
and [20] doses of finasteride (0.7, 7 and 70 mg/kg/day) and dutasteride (1, 10, 100 mg/kg/day) 
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[19]. In summary, although we did not see an effect of either finasteride or dutasteride on the 
growth of WPE1-NA22 xenografts, the decrease in the prostate and seminal vesicle weights 
suggest that the inhibitors were effective in inhibiting their respective 5α-reductase enzyme(s). 
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Appendix A - Tumor Area (n = 20-24) 
 
Figure A.1 Tumor area (n= 20-24)  
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Appendix B - Body Weight (n = 10-12) 
 
 
Figure B.1 Body weight (n = 10-12) 
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